Antengene Corporation Closes US$97M in Partial Series C Financing
Funding will be used to enhance R&D capacity and strengthen existing infrastructure Antengene Corporation, an innovative hematology and oncology-focused biopharmaceutical company, announced on July 20 that it had successfully closed US$97 million in Series C financing, to support ongoing drug development and preparations for potential commercialization. The financing was led by Fidelity Management & Research […]
Antengene Corporation Closes US$97M in Partial Series C Financing Read More »
Funding will be used to enhance R&D capacity and strengthen existing infrastructure Antengene Corporation, an innovative hematology and oncology-focused biopharmaceutical company, announced on July 20 that it had successfully closed US$97 million in Series C financing, to support ongoing drug development and preparations for potential commercialization. The financing was led by Fidelity Management & Research






